426 related articles for article (PubMed ID: 17925313)
1. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.
Lassere MN
Stat Methods Med Res; 2008 Jun; 17(3):303-40. PubMed ID: 17925313
[TBL] [Abstract][Full Text] [Related]
2. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Lassere MN; Johnson KR; Boers M; Tugwell P; Brooks P; Simon L; Strand V; Conaghan PG; Ostergaard M; Maksymowych WP; Landewe R; Bresnihan B; Tak PP; Wakefield R; Mease P; Bingham CO; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
J Rheumatol; 2007 Mar; 34(3):607-15. PubMed ID: 17343307
[TBL] [Abstract][Full Text] [Related]
3. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
Alonso A; Geys H; Molenberghs G; Kenward MG; Vangeneugden T
Biometrics; 2004 Dec; 60(4):845-53. PubMed ID: 15606404
[TBL] [Abstract][Full Text] [Related]
4. Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
Weir CJ; Walley RJ
Stat Med; 2006 Jan; 25(2):183-203. PubMed ID: 16252272
[TBL] [Abstract][Full Text] [Related]
5. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.
Maksymowych WP; Fitzgerald O; Wells GA; Gladman DD; Landewé R; Ostergaard M; Taylor WJ; Christensen R; Tak PP; Boers M; Syversen SW; Bathon JM; Ritchlin CJ; Mease PJ; Bykerk VP; Garnero P; Geusens P; El-Gabalawy H; Aletaha D; Inman RD; Kraus VB; Kvien TK; van der Heijde D
J Rheumatol; 2009 Aug; 36(8):1792-9. PubMed ID: 19671814
[TBL] [Abstract][Full Text] [Related]
6. Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.
Lassere M; Johnson K; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
J Rheumatol; 2007 Mar; 34(3):616-9. PubMed ID: 17343308
[TBL] [Abstract][Full Text] [Related]
7. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).
Lassere MN; Johnson KR; Schiff M; Rees D
BMC Med Res Methodol; 2012 Mar; 12():27. PubMed ID: 22409774
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.
Colburn WA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1419-27. PubMed ID: 11185662
[TBL] [Abstract][Full Text] [Related]
9. Alternative methods to evaluate trial level surrogacy.
Abrahantes JC; Shkedy Z; Molenberghs G
Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
[TBL] [Abstract][Full Text] [Related]
10. A unifying approach for surrogate marker validation based on Prentice's criteria.
Alonso A; Molenberghs G; Geys H; Buyse M; Vangeneugden T
Stat Med; 2006 Jan; 25(2):205-21. PubMed ID: 16220497
[TBL] [Abstract][Full Text] [Related]
11. Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints.
Alonso A; Molenberghs G; Burzykowski T; Renard D; Geys H; Shkedy Z; Tibaldi F; Abrahantes JC; Buyse M
Biometrics; 2004 Sep; 60(3):724-8. PubMed ID: 15339295
[TBL] [Abstract][Full Text] [Related]
12. An entropy-based nonparametric test for the validation of surrogate endpoints.
Miao X; Wang YC; Gangopadhyay A
Stat Med; 2012 Jun; 31(14):1517-30. PubMed ID: 22344829
[TBL] [Abstract][Full Text] [Related]
13. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer.
Hughes MD
Stat Methods Med Res; 2008 Oct; 17(5):487-95. PubMed ID: 18285440
[TBL] [Abstract][Full Text] [Related]
14. Potential surrogate endpoints in cancer research--some considerations and examples.
Duffy SW; Treasure FP
Pharm Stat; 2011; 10(1):34-9. PubMed ID: 20029937
[TBL] [Abstract][Full Text] [Related]
15. Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia.
Deslandes E; Chevret S
Stat Med; 2007 Dec; 26(30):5411-21. PubMed ID: 18058850
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
Manchikanti L; Datta S; Smith HS; Hirsch JA
Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
[TBL] [Abstract][Full Text] [Related]
17. Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints.
Pryseley A; Tilahun A; Alonso A; Molenberghs G
Clin Trials; 2007; 4(6):587-97. PubMed ID: 18042568
[TBL] [Abstract][Full Text] [Related]
18. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
Baker SG
Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
[TBL] [Abstract][Full Text] [Related]
19. Does the Prentice criterion validate surrogate endpoints?
Berger VW
Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
[TBL] [Abstract][Full Text] [Related]
20. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
